Archive for May 2nd, 2011

SGEN brentuximab vedotin PDUFA date announced

May 02, 2011 No Comments by

Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that the FDA has accepted for filing two Biologics License Applications (BLAs) for brentuximab vedotin, including one for the treatment of patients with relapsed or refractory Hodgkin lymphoma and one for the treatment of patients with relapsed or refractory systemic anaplastic large cell lymphoma (ALCL). A six-month priority […]

Daily News Read more